Get started
Regulus Therapeutics Inc.Regulus Therapeutics Inc.Regulus Therapeutics Inc.

Regulus Therapeutics Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

RGLS trade ideas

RGLS Showing Interesting LevelsRGLS continues pivoting around that 618 Fib line. Overall, it has held a clear uptrend despite the pullback. Trend line lines up almost perfectly with the latest higher lows put in. RNA companies remain a focus. In this case, it's not covid but kidney diseases. "In mid-May, Regulus Therapeutics announced an incremental update of its autosomal dominant polycystic kidney disease program. The CEO of the company, Jay Hagan said, “As previously reported, the ninth and final patient was trending well at the end of the dosing period and saw their polycystin levels continue to rise until study completion, twenty-eight days after the last dose. This pattern was generally consistent across the first cohort and further enhanced the overall mean changes from baseline for both biomarkers." PLUS upcoming presentation of RGLS4326 for the treatment of ADPKD at the PKD Connect Conference 2021 this Friday (6/25) could be something to keep in mind right now too. Quote Source: 7 Hot Penny Stocks to Watch That Are Trending Right Now
NASDAQ:RGLS
by PennyStocks101
RGLS RGLS .. We are in full phase two COVID-19. There are many aspects and many pharmaceutical companies that are trying to shine, especially in the research and experimentation of drugs of all kinds ... Let's add that a Master of Biotech finance like Steven Cohen buys 8.5% of shares (5.6 million shares). .. Remember what happened to COCP when Cohen himself bought 2.5% of shares (2.5 million shares) and went from 0.8 to 2.5 in a week ... so beware so maximum long alert .. I make you a super Christmas gift in advance. Happy trading everyone.
NASDAQ:RGLSLong
by mauretto432
7
$RGLS is gonna fall todayPupm&Dump trading strategy idea. $RGLS is rising without clear preconditions today. The demand for shares of the company looks lower than the supply. This and other conditions can cause a fall in the share price today. So I opened a short position from $0,95; stop-loss — $1,08; take-profit — $0,92; Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:RGLSShort
by KozakHlib
2
$RGLS 40% upside potential Regulus Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in September 2007 and is headquartered in San Diego, CA.
NASDAQ:RGLSLong
by DEXWireNews
$RGLS break out pattern / low volume - swing ideaPossible break out soon. Low Risk / Reward to 50 dma Reason: Stair stepping on daily making higher lows Low volume Indicator: RSI is at 45 and has been increasing (not overbought yet) MACD still in negative so this might spike soon. Recent offering in 2018 had created a sell off and currently accumulation has been steadily moving the price higher. Higher Lows Other reasons that looks promising: New: Patent approval finance.yahoo.com Insider buyers finance.yahoo.com Trade Idea: Swing: buy near 1.10-1.13 or within the black dash line Daytrade: wait for break of 1.23 or safer 1.25 (watch for news or volume to enter as this has low volume) Remember to: Trade with a plan, set your stop loss, take profits at any spike above 8% (rinse and repeat)
NASDAQ:RGLS
by work1411
RGLS - Fallen angel setup Momentum long from $1, $2.50 Feb CallsRGLS forming a nice fallen angel formation. IT has significant insider buying. It has few moving average to overcome however it has very good upside potential as it is coming down from huge £20 area. To play this we would consider February 2018 $2.50 Calls, currently $0.08 * Trade Criteria * Date First Found- August 24, 2017 (Intraday Alert) Pattern/Why- Fallen angel setup Entry Target Criteria- Break of $1 (Hti August 24, 2017) Exit Target Criteria- Momentum Stop Loss Criteria- $0.88 Please check back for Trade updates. (Note: Trade update is little delayed here.)
NASDAQ:RGLSLong
by AcornWealthCorp